The main purpose of this study is to evaluate the safety and tolerability of LY3871801 when administered as multiple doses in Healthy Asian and Non-Asian Participants. The study will also evaluate the amount of LY3871801 that gets into the blood stream and how long it takes the body to get rid of it in these participants. The study will be conducted in two parts (A \& B). The study will last up to approximately 24 days excluding the screening period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
32
Altasciences Clinical Los Angeles, Inc
Cypress, California, United States
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Predose up to 24 days post dose
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3871801
PK: Cmax of LY3871801
Time frame: Predose on Day 1 up to postdose on Day 17
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3871801
PK: AUC of LY3871801
Time frame: Predose on Day 1 up to postdose on Day 17
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.